Wouter V. Vogel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Wouter V. Vogel has a total of 251 co-authors. Here are the top co-authors by number of shared publications:
- Jan-Jakob Sonke
The Netherlands Cancer Institute
6 shared publications Jeroen B. van de Kamer
Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
4 shared publications- Arthur Johannes Anthonius Theodorus Braat
Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands
3 shared publications - Berlinda Jantina de Wit-Van der Veen
Department of nuclear medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands
3 shared publications J. B. van de Kamer
Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
3 shared publicationsJ.-J. Sonke
Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
3 shared publications
Latest Publications
- Open Access
- 13 October 2026
- Published by Wiley in BJU International
[ 18 F] fluorodeoxyglucose PET/CT refines staging and treatment selection in high‐risk upper tract urothelial carcinoma
Objectives: To evaluate the incremental clinical value of [ 18 F]fluorodeoxyglucose positron emission tomography/computed tomography ([ 18 F]FDG‐PET/CT) beyond contrast‐enhanced computed tomography (CECT) for primary staging of suspected high‐risk upper tract urothelial carcinoma (UTUC). Patients and Methods: We conducted a consecutive paired‐imaging cohort study of patients with suspected high‐risk UTUC undergoing primary staging with both CECT and [ 18 F]FDG‐PET/CT at a tertiary cancer centre between 2013 and 2025. The primary outcome was clinically relevant stage migration, defined as a transition between non‐metastatic and metastatic disease, and its impact on multidisciplinary treatment recommendation. Secondary outcomes included diagnostic performance in cases with histopathological verification. Results: Among 203 patients, [ 18 F]FDG‐PET/CT resulted in stage migration in 45 (22%), predominantly through upstaging (39 patients [19%]), comprising regional nodal upstaging in 19 patients (9.4%) and distant metastatic upstaging in 22 (11%), with both occurring in two patients. [ 18 F]FDG‐PET/CT led to treatment modification in 43 patients (21%). Stage migration was more frequent in the presence of CECT‐suspicious lymph nodes (odds ratio 3.4, 95% confidence interval 1.6–7.3). Among the 62 patients with histopathological verification, [ 18 F]FDG‐PET/CT demonstrated significantly higher sensitivity for nodal metastases than CECT (74% vs 33%) with similar specificity (89% vs 86%). Limitations include the retrospective single‐centre design and incomplete pathological confirmation, mostly due to neoadjuvant treatment and omission of surgery in metastatic disease. Conclusion: [ 18 F]FDG‐PET/CT provides actionable staging information beyond CECT in high‐risk UTUC, leading to treatment modification in one in five patients and in half of those with CECT‐suspicious nodal disease. These findings support selective use of [ 18 F]FDG‐PET/CT in primary staging to refine treatment selection.
- 13 October 2026
- Published by Wiley in BJU International
Open Access[ 18 F] fluorodeoxyglucose PET/CT refines staging and treatment selection in high‐risk upper tract urothelial carcinoma
Objectives: To evaluate the incremental clinical value of [ 18 F]fluorodeoxyglucose positron emission tomography/computed tomography ([ 18 F]FDG‐PET/CT) beyond contrast‐enhanced computed tomography (CECT) for primary staging of suspected high‐risk upper tract urothelial carcinoma (UTUC). Patients and Methods: We conducted a consecutive paired‐imaging cohort study of patients with suspected high‐risk UTUC undergoing primary staging with both CECT and [ 18 F]FDG‐PET/CT at a tertiary cancer centre between 2013 and 2025. The primary outcome was clinically relevant stage migration, defined as a transition between non‐metastatic and metastatic disease, and its impact on multidisciplinary treatment recommendation. Secondary outcomes included diagnostic performance in cases with histopathological verification. Results: Among 203 patients, [ 18 F]FDG‐PET/CT resulted in stage migration in 45 (22%), predominantly through upstaging (39 patients [19%]), comprising regional nodal upstaging in 19 patients (9.4%) and distant metastatic upstaging in 22 (11%), with both occurring in two patients. [ 18 F]FDG‐PET/CT led to treatment modification in 43 patients (21%). Stage migration was more frequent in the presence of CECT‐suspicious lymph nodes (odds ratio 3.4, 95% confidence interval 1.6–7.3). Among the 62 patients with histopathological verification, [ 18 F]FDG‐PET/CT demonstrated significantly higher sensitivity for nodal metastases than CECT (74% vs 33%) with similar specificity (89% vs 86%). Limitations include the retrospective single‐centre design and incomplete pathological confirmation, mostly due to neoadjuvant treatment and omission of surgery in metastatic disease. Conclusion: [ 18 F]FDG‐PET/CT provides actionable staging information beyond CECT in high‐risk UTUC, leading to treatment modification in one in five patients and in half of those with CECT‐suspicious nodal disease. These findings support selective use of [ 18 F]FDG‐PET/CT in primary staging to refine treatment selection.
- Open Access
- 1 July 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (13) , 7671-7672
Insights from an unfortunate FDG contamination
- 1 July 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (13) , 7671-7672
Open AccessInsights from an unfortunate FDG contamination
- Open Access
- 27 May 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (10) , 5760-5773
PROQURE-I: a phase I study adding concurrent [177Lu]Lu-PSMA-617 to EBRT and ADT in curative intent treatment of N1 prostate cancer
Current treatment of N1M0 prostate cancer (PCa) with locoregional external beam radiotherapy (EBRT) and long-term androgen deprivation therapy (ADT) has suboptimal five-year recurrence-free rates. Adding [177Lu]Lu-PSMA-617 may improve tumour control and reduce reliance on long-term ADT. This phase-1 dose-escalation study explores the safety and tolerability of adding concurrent [177Lu]Lu-PSMA-617 with EBRT and ADT. In the multi-centre phase-1 dose-escalation study (PROQURE-I), treatment-naïve cT1-4N1M0 PCa patients received standard locoregional EBRT (25-35 fractions) and 2-3 years ADT with concurrent [177Lu]Lu-PSMA-617 to determine its maximum tolerated dose (MTD). Dose levels included one cycle (3, 6 or 9 GBq in week 2 of EBRT) or two cycles (2 × 7.4 GBq in week 2 and 4). Grade ≥ 3 toxicity (CTCAE v5.0) was dose-limiting. Tumour and organ dosimetry was performed with SPECT/CT and planar imaging at 4, 24 and 168 h post-injection. Fourteen patients were included. No dose-limiting toxicity was observed and the MTD was not reached. Reported grade 1-2 toxicities were related to EBRT. Median absorbed dose to the primary tumour of 0.71 Gy/GBq (interquartile range (IQR) 0.5-2.9) at the 9 GBq; 0.91 Gy/GBq (IQR 0.6-1.0) at 7.4 GBq cycle 1; and 0.47 Gy/GBq (0.3-0.5) at cycle 2. Concurrent [177Lu]Lu-PSMA-617 with EBRT and ADT is safe and well tolerated in treatment-naïve N1M0 PCa. Clinical efficacy should be evaluated in a subsequent phase 2 study.
- 27 May 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (10) , 5760-5773
Open AccessPROQURE-I: a phase I study adding concurrent [177Lu]Lu-PSMA-617 to EBRT and ADT in curative intent treatment of N1 prostate cancer
Current treatment of N1M0 prostate cancer (PCa) with locoregional external beam radiotherapy (EBRT) and long-term androgen deprivation therapy (ADT) has suboptimal five-year recurrence-free rates. Adding [177Lu]Lu-PSMA-617 may improve tumour control and reduce reliance on long-term ADT. This phase-1 dose-escalation study explores the safety and tolerability of adding concurrent [177Lu]Lu-PSMA-617 with EBRT and ADT. In the multi-centre phase-1 dose-escalation study (PROQURE-I), treatment-naïve cT1-4N1M0 PCa patients received standard locoregional EBRT (25-35 fractions) and 2-3 years ADT with concurrent [177Lu]Lu-PSMA-617 to determine its maximum tolerated dose (MTD). Dose levels included one cycle (3, 6 or 9 GBq in week 2 of EBRT) or two cycles (2 × 7.4 GBq in week 2 and 4). Grade ≥ 3 toxicity (CTCAE v5.0) was dose-limiting. Tumour and organ dosimetry was performed with SPECT/CT and planar imaging at 4, 24 and 168 h post-injection. Fourteen patients were included. No dose-limiting toxicity was observed and the MTD was not reached. Reported grade 1-2 toxicities were related to EBRT. Median absorbed dose to the primary tumour of 0.71 Gy/GBq (interquartile range (IQR) 0.5-2.9) at the 9 GBq; 0.91 Gy/GBq (IQR 0.6-1.0) at 7.4 GBq cycle 1; and 0.47 Gy/GBq (0.3-0.5) at cycle 2. Concurrent [177Lu]Lu-PSMA-617 with EBRT and ADT is safe and well tolerated in treatment-naïve N1M0 PCa. Clinical efficacy should be evaluated in a subsequent phase 2 study.
- 14 May 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 222, 111551
Simultaneous concurrent chemoradiation and SBRT in stage III NSCLC: Safety report of the phase I hybrid trial
- 14 May 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 222, 111551
Simultaneous concurrent chemoradiation and SBRT in stage III NSCLC: Safety report of the phase I hybrid trial
- Open Access
- 6 April 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 59, 101161
Oncological outcomes following PSMA PET/CT-guided salvage whole-pelvis radiotherapy for recurrent prostate cancer
- 6 April 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 59, 101161
Open AccessOncological outcomes following PSMA PET/CT-guided salvage whole-pelvis radiotherapy for recurrent prostate cancer
- Open Access
- 17 March 2026
- Published by Springer Nature in EJNMMI Physics
- Vol. 13 (1)
Smart scanning for two: [18F]FDG dose optimization for pregnant patients using LAFOV PET/CT technology
This study aimed to evaluate the image quality-dose trade-off in pregnant patients imaged with long-axial field-of-view [18F]FDG PET/CT and to identify the
- 17 March 2026
- Published by Springer Nature in EJNMMI Physics
- Vol. 13 (1)
Open AccessSmart scanning for two: [18F]FDG dose optimization for pregnant patients using LAFOV PET/CT technology
This study aimed to evaluate the image quality-dose trade-off in pregnant patients imaged with long-axial field-of-view [18F]FDG PET/CT and to identify the
- Open Access
- 28 October 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (4) , 2217-2233
[18F]FDG-PET/CT’s change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trial
Purpose Ultra-short immunotherapy may spare cutaneous squamous cell carcinoma (CSCC) patients from mutilating surgery, but early identification of (non-)response is needed to safely guide treatment adaptation. This study evaluated the feasibility of sequential [18F]FDG-PET/CT (FDG-PET) as a response biomarker in resectable CSCC patients. Methods In the MATISSE, a randomized phase-II trial, 50 CSCC patients received two courses of neoadjuvant nivolumab (weeks 0 and 2) with or without low-dose ipilimumab (week 0) before surgery (week 4). FDG-PET scans were obtained pre-treatment and shortly prior to surgery to assess the change (Δ) in maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) at the primary tumour and largest (= index) lymph node metastasis (ILN). ΔMTV50%/4.0 and ΔTLG50%/4.0 were calculated using thresholds of 50% SUVmax and SUV ≥ 4.0. Results In 42 evaluable patients, 31 (74%) patients showed major or partial responses to immunotherapy. EORTC-criteria underestimated response but accurately identified non-responders (70% sensitivity, 100% specificity). In 28 primary tumours and 22 ILNs, a significant reduction in median SUVmax, MTV50%, MTV4.0, TLG50%, and TLG4.0 was observed in responders versus non-responders (overall, p ≤ 0.004, and p ≤ 0.03, respectively). ΔTLG50% and ΔTLG4.0 correlated strongly with response (primary: 92% and 96% accuracy; ILN: 91% and 89% accuracy). Conclusions Quantitative FDG-PET-response assessment allows early identification of (non-)responders upon neoadjuvant immunotherapy prior to surgery in locoregionally advanced CSCC patients. Early changes in FDG-PET’s TLG can support future trials aiming at safe de-escalation of current standard of care surgery with or without adjuvant radiotherapy. Trial registration: EudraCT 2020–001074-30. Registered 9 March 2020, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001074-30
- 28 October 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (4) , 2217-2233
Open Access[18F]FDG-PET/CT’s change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trial
Purpose Ultra-short immunotherapy may spare cutaneous squamous cell carcinoma (CSCC) patients from mutilating surgery, but early identification of (non-)response is needed to safely guide treatment adaptation. This study evaluated the feasibility of sequential [18F]FDG-PET/CT (FDG-PET) as a response biomarker in resectable CSCC patients. Methods In the MATISSE, a randomized phase-II trial, 50 CSCC patients received two courses of neoadjuvant nivolumab (weeks 0 and 2) with or without low-dose ipilimumab (week 0) before surgery (week 4). FDG-PET scans were obtained pre-treatment and shortly prior to surgery to assess the change (Δ) in maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) at the primary tumour and largest (= index) lymph node metastasis (ILN). ΔMTV50%/4.0 and ΔTLG50%/4.0 were calculated using thresholds of 50% SUVmax and SUV ≥ 4.0. Results In 42 evaluable patients, 31 (74%) patients showed major or partial responses to immunotherapy. EORTC-criteria underestimated response but accurately identified non-responders (70% sensitivity, 100% specificity). In 28 primary tumours and 22 ILNs, a significant reduction in median SUVmax, MTV50%, MTV4.0, TLG50%, and TLG4.0 was observed in responders versus non-responders (overall, p ≤ 0.004, and p ≤ 0.03, respectively). ΔTLG50% and ΔTLG4.0 correlated strongly with response (primary: 92% and 96% accuracy; ILN: 91% and 89% accuracy). Conclusions Quantitative FDG-PET-response assessment allows early identification of (non-)responders upon neoadjuvant immunotherapy prior to surgery in locoregionally advanced CSCC patients. Early changes in FDG-PET’s TLG can support future trials aiming at safe de-escalation of current standard of care surgery with or without adjuvant radiotherapy. Trial registration: EudraCT 2020–001074-30. Registered 9 March 2020, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001074-30
- 27 May 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (8) , e469-e476
Imaging Proliferation of Stage IV Cutaneous Melanoma With 18F-FLT PET/CT
Background: 18F-FLT PET/CT visualizes cellular proliferation and may correlate more directly with tumor aggressiveness and treatment response than 18F-FDG PET/CT in melanoma patients treated with BRAF/MEK inhibitors. We aimed to assess whether 18F-FLT PET/CT can predict early resistance to BRAF/MEK inhibitors in addition to current clinical tools in patients with BRAF-mutated metastatic melanoma. Patients and Methods: This explorative side study of the phase II multicenter REPOSIT trial included 19 patients with stage IV BRAF V600E/K-mutated cutaneous melanoma who underwent optional 18F-FLT PET/CT. 18F-FLT PET/CT was performed at baseline and after 2 weeks of treatment to evaluate baseline uptake and early changes in metabolic activity. 18F-FDG PET/CT was performed at baseline for comparison. Ki67 expression was assessed in metastatic tissue samples. Analyses included: (1) visual comparison of baseline 18F-FLT and 18F-FDG uptake, (2) correlation of 18F-FLT uptake with Ki-67, (3) semiquantitative analysis of baseline 18F-FLT uptake, and (4) evaluation of percentage change in 18F-FLT uptake after 2 weeks. Results: Patients with consistently lower 18F-FLT than 18F-FDG uptake in metastases had longer progression-free survival (PFS; median 9.6 months, range: 3.4 to 32.3) compared with those with equal/higher or heterogeneous 18F-FLT uptake (3.5 to 5.3 mo). Baseline 18F-FLT SULpeak did not correlate with Ki67 expression (P = 0.601), nor was Ki67 associated with PFS (P = 0.39). No significant PFS difference was observed between patients with baseline 18F-FLT SULpeak below or above the median (P = 0.601). However, a greater percentage decrease in 18F-FLT uptake at 2 weeks was associated with longer PFS (median: 13.9 vs 4.3 mo, P = 0.005). Conclusions: Baseline 18F-FLT uptake patterns relative to 18F-FDG, and early changes in 18F-FLT uptake, were associated with PFS in patients treated with BRAF/MEK inhibitors. These explorative findings suggest that 18F-FLT PET/CT may have predictive value, warranting confirmation in larger prospective studies.
- 27 May 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (8) , e469-e476
Imaging Proliferation of Stage IV Cutaneous Melanoma With 18F-FLT PET/CT
Background: 18F-FLT PET/CT visualizes cellular proliferation and may correlate more directly with tumor aggressiveness and treatment response than 18F-FDG PET/CT in melanoma patients treated with BRAF/MEK inhibitors. We aimed to assess whether 18F-FLT PET/CT can predict early resistance to BRAF/MEK inhibitors in addition to current clinical tools in patients with BRAF-mutated metastatic melanoma. Patients and Methods: This explorative side study of the phase II multicenter REPOSIT trial included 19 patients with stage IV BRAF V600E/K-mutated cutaneous melanoma who underwent optional 18F-FLT PET/CT. 18F-FLT PET/CT was performed at baseline and after 2 weeks of treatment to evaluate baseline uptake and early changes in metabolic activity. 18F-FDG PET/CT was performed at baseline for comparison. Ki67 expression was assessed in metastatic tissue samples. Analyses included: (1) visual comparison of baseline 18F-FLT and 18F-FDG uptake, (2) correlation of 18F-FLT uptake with Ki-67, (3) semiquantitative analysis of baseline 18F-FLT uptake, and (4) evaluation of percentage change in 18F-FLT uptake after 2 weeks. Results: Patients with consistently lower 18F-FLT than 18F-FDG uptake in metastases had longer progression-free survival (PFS; median 9.6 months, range: 3.4 to 32.3) compared with those with equal/higher or heterogeneous 18F-FLT uptake (3.5 to 5.3 mo). Baseline 18F-FLT SULpeak did not correlate with Ki67 expression (P = 0.601), nor was Ki67 associated with PFS (P = 0.39). No significant PFS difference was observed between patients with baseline 18F-FLT SULpeak below or above the median (P = 0.601). However, a greater percentage decrease in 18F-FLT uptake at 2 weeks was associated with longer PFS (median: 13.9 vs 4.3 mo, P = 0.005). Conclusions: Baseline 18F-FLT uptake patterns relative to 18F-FDG, and early changes in 18F-FLT uptake, were associated with PFS in patients treated with BRAF/MEK inhibitors. These explorative findings suggest that 18F-FLT PET/CT may have predictive value, warranting confirmation in larger prospective studies.
- Open Access
- 27 February 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (9) , 3058-3061
Clinical benefits of LAFOV PET/CT in growing demand for molecular imaging
- 27 February 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (9) , 3058-3061
Open AccessClinical benefits of LAFOV PET/CT in growing demand for molecular imaging
- Open Access
- 9 January 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 52, 100910
Relating proton LETd to biological response of parotid and submandibular glands using PSMA-PET in clinical patients
- 9 January 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 52, 100910
Open AccessRelating proton LETd to biological response of parotid and submandibular glands using PSMA-PET in clinical patients